Structured as a non-invasive way to treat and eradicate deadly cancers like GBM -- typically requiring debilitating brain surgery that, in turn, often leads to tumor recurrence - the founders of SonALAsense see the company and the treatment as the culmination of a life-long journey perhaps finally to beat the cancer scourge. Principals of the firm are developing a tumor-targeting drug (SONALA-001) together with MR-guided focused ultrasound as sonodynamic therapy (SDT) - a combination that has the potential to be a safe and effective noninvasive treatment for cancer - with SonALAsense being the first company to advance SDT into clinical trials.
